Vancouver, British Columbia - June 20, 2012 (Investorideas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM
, OTC: SRBCF, Frankfurt: ZSB), announced today results from a
preclinical study of its sodium glucose transporter (SGLT) inhibitor in
monkeys. When administered orally, Sirona Biochem’s SGLT inhibitor,
SBM-TFC-039, triggered glucosuria in a dose-dependent manner. In
addition, the glucosuria effect was robust for the full 24 hours
studied.
"At the recent American Diabetes Association meeting in
Philadelphia, it was apparent that SGLT inhibitors are a potentially
ground-breaking treatment for Type 2 diabetes," said Dr. Howard Verrico,
President and CEO of Sirona Biochem. "Preclinical results of our SGLT
inhibitor, SBM-TFC-039, in multiple species have consistently
demonstrated its efficacy and we are exploring data that may differentiate SBM-TFC-039 from the other SGLT inhibitors in development," he added.
SBM-TFC-039 is an SGLT inhibitor drug candidate for Type 2
diabetes. In the kidneys, SGLT inhibitors reduce the reabsorption of
glucose into the bloodstream by eliminating excess glucose into the
urine.
SBM-TFC-039 has been tested acutely and chronically in a rodent
diabetic model, in addition to the latest study in primates. In those
tests, SBM-TFC-039 has consistently demonstrated a glucose-lowering
effect in a dose-dependent manner.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes
therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging
agents for cosmetic use, and biological ingredients. The company
utilizes a proprietary chemistry technique to improve pharmaceutical
properties of carbohydrate-based molecules. For more information visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of release of the relevant information, unless explicitly stated
otherwise. Actual results, performance or achievement could differ
materially from those expressed in, or implied by, Sirona Biochem’s
forward-looking statements due to the risks and uncertainties inherent
in Sirona Biochem’s business including, without limitation, statements
about: the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval, producing
and marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and validity
of patent protection for its products; competition from other
pharmaceutical or biotechnology companies; and its ability to obtain
additional financing to support its operations. Sirona Biochem does not
assume any obligation to update any forward-looking statements except as
required by law.
Published at the Investorideas.com Newswire
Disclaimer http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com was not compensated for this news report
No comments:
Post a Comment